AUNA: Guidance Optimism vs. Operating Reality – Wait for Proof

What happened

Auna S.A. targets 12% EBITDA growth by 2026, citing Mexico stabilization, refinancing benefits, and hospital network gains, but FY25 results showed EBITDA margin compression to 19.6% and Mexico utilization dropping to 38.6%. The first quarter of 2026 delivered mixed KPIs—Mexico utilization of 39.4% versus 39.8% a year ago and emergency treatments down 2.3% YoY—indicating the recovery is not yet visible. The DeepValue master report maintains a WAIT rating at $5.20, with a base-case value of $5.80, contingent on clear Mexico volume inflection in 2Q/3Q26. Covenants remain tight, with leverage at 3.64x against a 3.90x ceiling through September 2026, leaving little room for error. Until operating data confirms the contracted channel wins translate into higher utilization, the equity remains a high-risk bet on a turnaround that has not materialized.

Implication

Investors should hold the WAIT rating until 2Q/3Q26 Mexico KPIs demonstrate sustained volume improvement. The upside scenario ($8.00) requires utilization and emergency visits to reverse YoY declines, while failure to do so could drive the stock toward the bear case of $3.20. Tight covenants add risk; any covenant breach or liquidity compression would severely impair equity value.

Thesis delta

The news article reiterates management's 2026 guidance but does not alter the core thesis. The WAIT rating remains, as the market already prices in a recovery that has yet to appear in actual utilization data. The delta is neutral: the positive headline does not provide new evidence of operational inflection, so the investment case still hinges on forthcoming KPI prints.